494 related articles for article (PubMed ID: 31538291)
1. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Vassilatou E
World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Song DK; Jung H; Jeong K; Chung H; Lee H
Sci Rep; 2023 Aug; 13(1):13397. PubMed ID: 37591864
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Harsha Varma S; Tirupati S; Pradeep TVS; Sarathi V; Kumar D
Diabetes Metab Syndr; 2019; 13(2):1065-1069. PubMed ID: 31336445
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome.
Doycheva I; Ehrmann DA
Fertil Steril; 2022 May; 117(5):897-911. PubMed ID: 35512974
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
[TBL] [Abstract][Full Text] [Related]
7. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
[TBL] [Abstract][Full Text] [Related]
8. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
Jeanes YM; Reeves S
Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
10. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
Macut D; Božić-Antić I; Bjekić-Macut J; Tziomalos K
Eur J Endocrinol; 2017 Sep; 177(3):R145-R158. PubMed ID: 28694246
[TBL] [Abstract][Full Text] [Related]
11. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.
Kumarendran B; O'Reilly MW; Manolopoulos KN; Toulis KA; Gokhale KM; Sitch AJ; Wijeyaratne CN; Coomarasamy A; Arlt W; Nirantharakumar K
PLoS Med; 2018 Mar; 15(3):e1002542. PubMed ID: 29590099
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
[TBL] [Abstract][Full Text] [Related]
13. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
Brzozowska MM; Ostapowicz G; Weltman MD
J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
[TBL] [Abstract][Full Text] [Related]
14. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
Targher G; Rossini M; Lonardo A
Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
[TBL] [Abstract][Full Text] [Related]
15. Hepatic manifestations of women with polycystic ovary syndrome.
Chen MJ; Ho HN
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
[TBL] [Abstract][Full Text] [Related]
16. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease.
Vassilatou E; Vassiliadi DA; Salambasis K; Lazaridou H; Koutsomitopoulos N; Kelekis N; Kassanos D; Hadjidakis D; Dimitriadis G
Eur J Endocrinol; 2015 Dec; 173(6):739-47. PubMed ID: 26340970
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
Rocha ALL; Faria LC; Guimarães TCM; Moreira GV; Cândido AL; Couto CA; Reis FM
J Endocrinol Invest; 2017 Dec; 40(12):1279-1288. PubMed ID: 28612285
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.
Petta S; Ciresi A; Bianco J; Geraci V; Boemi R; Galvano L; Magliozzo F; Merlino G; Craxì A; Giordano C
PLoS One; 2017; 12(11):e0186136. PubMed ID: 29161258
[TBL] [Abstract][Full Text] [Related]
19. Hepatokines: the missing link in the development of insulin resistance and hyperandrogenism in PCOS?
Stefanaki K; Ilias I; Paschou SA; Karagiannakis DS
Hormones (Athens); 2023 Dec; 22(4):715-724. PubMed ID: 37704921
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of nonalcoholic fatty liver disease increased with type 2 diabetes mellitus in overweight/obese youth with polycystic ovary syndrome.
Patel-Sanchez N; Perito E; Tsai P; Raymond-Flesch M; Lodish M; Sarkar M
J Pediatr Endocrinol Metab; 2023 May; 36(5):441-446. PubMed ID: 37060356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
